Citations

Clear

959 citation(s) found for "Service, F J".

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Lacouture, Mario E. , Dréno, Brigitte , Ascierto, Paolo A. , Dummer, Reinhard , Basset‐Séguin, Nicole , Fife, Kate , Ernst, Scott , Licitra, Lisa , Neves, Rogerio I. , Peris, Ketty , Puig, Susana , Sokolof, Jonas, Sekulić, Aleksandar , Kunstfeld, Rainer , Hauschild, Axel , Licitra, Lisa , Puig, Susana

Mayo Clinic

The Oncologist | August 10, 2016 | Volume: 21 | Issue: 10 | Pages: 1218-1229

10.1634/theoncologist.2016-0186 | PMID 27511905 Get It

Abstract Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell carcinoma (BCC). Vismodegib, a first-in-class small-molecule inhibitor of hedgehog pathway signaling, is approved by regulatory authorities for the treatment of adults who have metastatic BCC or locally advanced BCC that has recurred after surgery, or who are not candidates for surgery and who are not candidates for radiation. A second inhibitor, sonidegib, was also recently approved for the same patient group with locally advanced BCC. Adverse events (AEs) commonly observed in hedgehog pathway inhibitor (HPI)-treated patients include muscle spasms, ageusia/dysgeusia, alopecia, weight loss, and asthenia (fatigue). These AEs are thought to be mechanistically related to inhibition of the hedgehog pathway in normal tissue. Although the severity of the majority of AEs associated with HPIs is grade 1–2, the long-term nature of these AEs can lead to decreased quality of life, treatment interruption, and in some cases discontinuation, all of which might affect clinical outcome. The incidence, clinical presentation, putative mechanisms, and management strategies for AEs related to HPIs in advanced BCC are described. These observations represent the first step toward the development of mechanism-based preventive and management strategies. Knowledge of these AEs will allow health care professionals to provide appropriate counseling and supportive care interventions, all of which will contribute to improved quality of life and optimal benefit from therapy.
Are short (blue) wavelengths necessary for light treatment of seasonal affective disorder?
Anderson, Janis L. , Hilaire, Melissa A. St. , Auger, R. Robert , Glod, Carol A., Rivera, Adreanne, Salgado, S. M. Fuentes, Pullen, Samuel J. , Kaufman, Tara K. , Selby, A. J., Wolfe, David J., Crow, Scott J.

Mayo Clinic

Chronobiology International | August 5, 2016 | Volume: 33 | Issue: 9 | Pages: 1267-1279

10.1080/07420528.2016.1207660 | PMID 27494399 Get It

Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII
Kumar, Anita J. , Gimotty, Phyllis A. , Gelfand, Joel M. , Buck, Georgina , Rowe, Jacob M. , Goldstone, Anthony H., Marks, David I. , Litzow, Mark R. , Paietta, Elisabeth , Tallman, Martin S. , Luger, Selina M. , Loren, Alison W. , Fielding, Adele K. , Lazarus, Hillard M.

Mayo Clinic

American Journal of Hematology | July 28, 2016 | Volume: 91 | Issue: 11 | Pages: 1107-1112

10.1002/ajh.24497 | PMID 27468137 Get It

Adults with acute lymphoblastic leukemia (ALL) have a poorer prognosis than children due to a high risk of relapse. One explanation may be variable adherence to dose‐intense chemotherapy. However, little is known about risk factors for delays in therapy and their impact on survival. We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL. Logistic regression was used to identify risk factors for a very long delay (VLD, >4 weeks) in start of intensification therapy. Cox regression was used to evaluate the impact of delays on overall survival (OS) and event‐free survival (EFS). We evaluated 1076 Philadelphia chromosome negative (Ph−) patients who completed induction chemotherapy, achieved complete remission, and started intensification. Factors independently associated with VLD included duration of hospitalization (odds ratio [OR] = 1.2, P < 0.001) during Phase I; thrombocytopenia during Phase I (OR = 1.16, P = 0.004) or Phase II (OR 1.13, P = 0.001); chemotherapy dose reductions during Induction Phase I (OR = 1.72, P < 0.014); female sex (OR = 1.53, P = 0.010); Black (OR = 3.24, P = 0.003) and Asian (OR = 2.26, P = 0.021) race; and increasing age (OR = 1.31, P < 0.001). In multivariate Cox regression, patients who underwent allogeneic stem cell transplant (alloHCT) had significantly worse OS (HR 1.4, P = 0.03) and EFS (HR 1.4, P = 0.02) after experiencing a VLD compared to alloHCT patients who experienced ≤4 weeks delay. Specific populations (female, older, Black, and Asian patients) were more likely to experience delays in chemotherapy, as were those with significant toxicity during induction. VLDs in therapy negatively affected outcomes in patients undergoing allografting. Am. J. Hematol. 91:1107–1112, 2016. © 2016 Wiley Periodicals, Inc.
Telomere structure and maintenance gene variants and risk of five cancer types
Karami, Sara , Pierce, Brandon L. , Nutter, Ellen L., Schumacher, Fredrick R. , Lindström, Sara , Witte, John S. , Fang, Shenying , Han, Jiali , Kraft, Peter , Song, Fengju , Hung, Rayjean J., McKay, James , Gruber, Stephen B. , Risch, Angela , Shen, Hongbing , Haiman, Christopher A. , Boardman, Lisa, Casey, Graham , Peters, Ulrike , Olama, Ali Amin Al , Berndt, Sonja I. , Brennan, Paul , Brenner, Hermann , Brinton, Louise A. , Caporaso, Neil E. , Chang‐Claude, Jenny , Cunningham, Julie M. , Easton, Douglas F. , Eeles, Rosalind A. , Eisen, Timothy, Gala, Manish , Gallinger, Steven , Gayther, Simon A. , Goode, Ellen L. , Grönberg, Henrik , Henderson, Brian E., Houlston, Richard S. , Joshi, Amit D. , Küry, Sébastien , Landi, Mari T., Muir, Kenneth , Permuth‐Wey, Jenny, Phelan, Catherine, Ramus, Susan J. , Schildkraut, Joellen M. , Slattery, Martha L. , Song, Honglin , Wentzensen, Nicolas , Zanke, Brent W., Sellers, Thomas A. , Zheng, Wei , Chatterjee, Nilanjan , TRICL, on behalf of GECCO and the GAME‐ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and, Hung, Rayjean J. , Han, Younghun , Pande, Mala , Cheng, Iona C. , Rudd, James , Kote‐Jarai, Zsofia , Hunter, David J. , Hung, Rayjean J., Chanock, Stephen Jacob , Boardman, Lisa, Ulrich, Cornelia M. , Berchuck, Andrew , Bezieau, Stéphane , Chan, Andrew T. , Christiani, David C. , Marchand, Loı̈c Le , Newcomb, Polly A. , Pharoah, Paul D.P. , Potter, John D. , Risch, Harvey A. , White, Emily E. , Wiklund, Fredrik E. , Amos, Christopher I. , Doherty, Jennifer A. , TRICL, on behalf of GECCO and the GAME‐ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and, Ramus, Susan J , Houlston, Richard S , Eeles, Rosalind A , Hung, Rayjean J , Muir, Kenneth , Kury, Sebastien , Brenner, Hermann , Han, Jiali , Kraft, Peter , Zheng, Wei , Risch, Angela , Shen, Hongbing

Mayo Clinic

International Journal of Cancer | July 26, 2016 | Volume: 139 | Issue: 12 | Pages: 2655-2670

10.1002/ijc.30288 | PMID 27459707 Get It

Telomeres cap chromosome ends, protecting them from degradation, double‐strand breaks, and end‐to‐end fusions. Telomeres are maintained by telomerase, a reverse transcriptase encoded by TERT, and an RNA template encoded by TERC. Loci in the TERT and adjoining CLPTM1L region are associated with risk of multiple cancers. We therefore investigated associations between variants in 22 telomere structure and maintenance gene regions and colorectal, breast, prostate, ovarian, and lung cancer risk. We performed subset‐based meta‐analyses of 204,993 directly‐measured and imputed SNPs among 61,851 cancer cases and 74,457 controls of European descent. Independent associations for SNP minor alleles were identified using sequential conditional analysis (with gene‐level p value cutoffs ≤3.08 × 10−5). Of the thirteen independent SNPs observed to be associated with cancer risk, novel findings were observed for seven loci. Across the DCLRE1B region, rs974494 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Across the TERC region, rs75316749 was positively associated with colorectal, breast, ovarian, and lung cancers. Across the DCLRE1B region, rs974404 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Near POT1, rs116895242 was inversely associated with colorectal, ovarian, and lung cancers, and RTEL1 rs34978822 was inversely associated with prostate and lung cancers. The complex association patterns in telomere‐related genes across cancer types may provide insight into mechanisms through which telomere dysfunction in different tissues influences cancer risk.
Establishing an Ambulatory Telemedicine Service in a Urology Practice
Rivera, Marcelino , O’Neil, Daniel A. , Montpetit, Andrew, Gettman, Matthew T., Viers, Boyd R.

Mayo Clinic

Videourology™ | July 26, 2016 | Volume: 30 | Issue: 4 | Pages: No page available

10.1089/vid.2016.0006 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2016.0006.M1 sj-vid-1-vid-10.1089_vid.2016.0006
Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
Hofheinz, Ralf‐Dieter , Deplanque, G., Kobayashi, Yoshimitsu, Ocvirk, Janja , Racca, Patrizia, Guenther, Silke, Lacouture, Mario E. , Jatoi, Aminah , Komatsu, Yoshito , Zhang, Jun

Mayo Clinic

The Oncologist | July 23, 2016 | Volume: 21 | Issue: 12 | Pages: 1483-1491

10.1634/theoncologist.2016-0051 | PMID 27449521 Get It

Abstract Inhibition of the epidermal growth factor receptor (EGFR) is an established treatment that extends patient survival across a variety of tumor types. EGFR inhibitors fall into two main categories: anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab, and first-generation tyrosine kinase inhibitors, such as afatinib, gefitinib, and erlotinib. Skin reactions are the most common EGFR inhibitor-attributable adverse event, resulting in papulopustular (acneiform) eruptions that can be painful and debilitating, and which may potentially have a negative impact on patients’ quality of life and social functioning, as well as a negative impact on treatment duration. Shortened treatment duration can, in turn, compromise antineoplastic efficacy. Similarly, appropriate management of skin reactions is dependent on their accurate grading; however, conventional means for grading skin reactions are inadequate, particularly within the context of clinical trials. Treating a skin reaction only once it occurs (reactive treatment strategies) may not be the most effective management approach; instead, prophylactic approaches may be preferable. Indeed, we support the viewpoint that prophylactic management of skin reactions should be recommended for all patients treated with EGFR inhibitors. Appropriate prophylactic management could effectively reduce the severity of skin reactions in patients treated with EGFR inhibitors and therefore has the potential to directly benefit patients and improve drug adherence. Accordingly, here we review published and still-emerging data, and provide practical and evidence-based recommendations and algorithms regarding the optimal prophylactic management of EGFR inhibitor-attributable skin reactions.
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
Arlt, Wiebke , Bancos, Irina , Dralle, Henning , Newell‐Price, John , Sahdev, Anju , Tabarin, Antoine , Tsagarakis, Stylianos , Dekkers, Olaf M, Dekkers, Olaf M. , Faßnacht, Martin , Terzolo, Massimo , Dekkers, Olaf M, Bancos, Irina , Arlt, Wiebke , Newell-Price, John , Dekkers, Olaf M

Mayo Clinic

European Journal of Endocrinology | July 7, 2016 | Volume: 175 | Issue: 2 | Pages: G1-G34

10.1530/eje-16-0467 | PMID 27390021 Get It

By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent conditions requiring therapeutic intervention (e.g. adrenocortical carcinoma, pheochromocytoma, hormone-producing adenoma or metastasis). The purpose of this guideline is to provide clinicians with best possible evidence-based recommendations for clinical management of patients with adrenal incidentalomas based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. We predefined four main clinical questions crucial for the management of adrenal incidentaloma patients, addressing these four with systematic literature searches: (A) How to assess risk of malignancy?; (B) How to define and manage low-level autonomous cortisol secretion, formerly called ‘subclinical’ Cushing’s syndrome?; (C) Who should have surgical treatment and how should it be performed?; (D) What follow-up is indicated if the adrenal incidentaloma is not surgically removed? Selected recommendations: (i) At the time of initial detection of an adrenal mass establishing whether the mass is benign or malignant is an important aim to avoid cumbersome and expensive follow-up imaging in those with benign disease. (ii) To exclude cortisol excess, a 1mg overnight dexamethasone suppression test should be performed (applying a cut-off value of serum cortisol ≤50nmol/L (1.8µg/dL)). (iii) For patients without clinical signs of overt Cushing’s syndrome but serum cortisol levels post 1mg dexamethasone >138nmol/L (>5µg/dL), we propose the term ‘autonomous cortisol secretion’. (iv) All patients with ‘(possible) autonomous cortisol’ secretion should be screened for hypertension and type 2 diabetes mellitus, to ensure these are appropriately treated. (v) Surgical treatment should be considered in an individualized approach in patients with ‘autonomous cortisol secretion’ who also have comorbidities that are potentially related to cortisol excess. (vi) In principle, the appropriateness of surgical intervention should be guided by the likelihood of malignancy, the presence and degree of hormone excess, age, general health and patient preference. (vii) Surgery is not usually indicated in patients with an asymptomatic, nonfunctioning unilateral adrenal mass and obvious benign features on imaging studies. We provide guidance on which surgical approach should be considered for adrenal masses with radiological findings suspicious of malignancy. Furthermore, we offer recommendations for the follow-up of patients with adrenal incidentaloma who do not undergo adrenal surgery, for those with bilateral incidentalomas, for patients with extra-adrenal malignancy and adrenal masses and for young and elderly patients with adrenal incidentalomas
Investigating the KNDy Hypothesis in Humans by Coadministration of Kisspeptin, Neurokinin B, and Naltrexone in Men
Narayanaswamy, Shakunthala, Prague, Julia , Papadopoulou, Deborah , Mizamtsidi, Maria, Shah, Amar, Bassett, Paul , Comninos, Alexander , Abbara, Ali , Veldhuis, Johannes D. , Dhillo, Waljit S. , Prague, Julia K, Jayasena, Channa N, Papadopoulou, Deborah A, Shah, Amar J, Comninos, Alexander N, Bloom, Stephen R. , Jayasena, Channa

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 5, 2016 | Volume: 101 | Issue: 9 | Pages: 3429-3436

10.1210/jc.2016-1911 | PMID 27379743 Get It

AbstractContext:A subpopulation of hypothalamic neurons colocalize three neuropeptides, namely kisspeptin, neurokinin B (NKB), and dynorphin, collectively termed KNDy neurons. Animal studies suggest they interact to affect pulsatile GnRH release (KNDy hypothesis); kisspeptin stimulates, NKB modulates, and dynorphin (an opioid) inhibits.Objective:To investigate the KNDy hypothesis in humans, we assessed for the first time the effects of the coadministration of kisspeptin-54, NKB, and an opioid receptor antagonist, naltrexone, on LH pulsatility (surrogate marker for GnRH pulsatility) and gonadotropin release.Design, Setting, and Participants:This was an ethically approved prospective, single-blinded, placebo-controlled study. Healthy male volunteers (n = 5/group) attended our research facility for eight study visits.Intervention and Main Outcome Measure:After 1 hour of baseline blood sampling, participants received a different intervention at each visit: oral 50 mg naltrexone, 8-hour iv infusions of vehicle, 2.56 nmol/kg · h NKB, 0.1 nmol/kg · h kissspeptin-54 (KP) alone and in combination. Frequent blood sampling to measure plasma gonadotropins and sex steroids was conducted and LH pulsatility was determined using blinded deconvolution analysis.Results:All kisspeptin and naltrexone containing groups potently increased LH and LH pulsatility (P &lt; .001 vs vehicle). NKB alone did not affect gonadotropins. NKB+KP had significantly lower increases in gonadotropins compared with kisspeptin alone (P &lt; .01). Naltrexone+KP was the only group to significantly increase LH pulse amplitude (P &lt; .001 vs vehicle).Conclusions:Our results suggest significant interactions between the KNDy neuropeptides on LH pulsatility and gonadotropin release in humans. This has important implications for improving our understanding of GnRH pulse generation in humans.
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
Castillo, Jorge J. , García‐Sánz, Ramón , Hatjiharissi, Evdoxia , Kyle, Robert A. , Leleu, Xavier , McMaster, Mary L. , Merlini, Giampaolo , Morra, Enrica, Owen, Roger G., Poulain, Stéphanie , Stone, Marvin J., Tam, Constantine S. , Varettoni, Marzia , Dimopoulos, Meletios Α. , Kastritis, Efstathios , Minnema, Monique C , Treon, Steven P. , Merlini, Giampaolo , Dimopoulos, Meletios A , Tam, Constantine S , Kastritis, Efstathios , Garcia-Sanz, Ramon , Castillo, Jorge J , Varettoni, Marzia

Mayo Clinic

British Journal of Haematology | July 5, 2016 | Volume: 175 | Issue: 1 | Pages: 77-86

10.1111/bjh.14196 | PMID 27378193 Get It

SummaryThe diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi‐institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history‐taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing‐Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Lesokhin, Alexander M. , Ansell, Stephen M. , Armand, Philippe , Halwani, Ahmad , Gutierrez, Martin , Millenson, Michael, Cohen, Adam D. , Lebovic, Daniel, Dhodapkar, Madhav V. , Avigan, David , Chapuy, Bjoern , Ligon, Azra H. , Freeman, Gordon J. , Cattry, Deepika, Zhu, Lili, Grosso, Joseph F., Garelik, M. Brigid, Borrello, Ivan , Timmerman, John M. , Scott, Emma C. , Millenson, Michael M, Schuster, Stephen J. , Dhodapkar, Madhav, Rodig, Scott J, Bradley Garelik, M Brigid, Shipp, Margaret A, Timmerman, John, Scott, Emma , Rodig, Scott J , Zhu, Lili, Shipp, Margaret Ann , Lesokhin, Alexander M , Cohen, Adam D

Mayo Clinic

Journal of Clinical Oncology | June 6, 2016 | Volume: 34 | Issue: 23 | Pages: 2698-2704

10.1200/jco.2015.65.9789 | PMID 27269947 Get It

Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies. Methods In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti–PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression. Results Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks. Conclusion Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.